Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

Crowther, Michael D., Dolton, Garry, Legut, Mateusz, Caillaud, Marine E., Lloyd, Angharad, Attaf, Meriem, Galloway, Sarah A. E., Rius, Cristina, Farrell, Colin P., Szomolay, Barbara ORCID: https://orcid.org/0000-0002-5375-5533, Ager, Ann ORCID: https://orcid.org/0000-0002-5763-8908, Parker, Alan L. ORCID: https://orcid.org/0000-0002-9302-1761, Fuller, Anna, Donia, Marco, McCluskey, James, Rossjohn, Jamie ORCID: https://orcid.org/0000-0002-2020-7522, Svane, Inge Marie, Phillips, John D. and Sewell, Andrew K. ORCID: https://orcid.org/0000-0003-3194-3135 2020. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology 21 , 178 - 185. 10.1038/s41590-019-0578-8

[thumbnail of 32900_3_merged_1575993704.pdf]
Preview
PDF - Accepted Post-Print Version
Download (15MB) | Preview

Abstract

Human leukocyte antigen (HLA)-independent, T cell–mediated targeting of cancer cells would allow immune destruction of malignancies in all individuals. Here, we use genome-wide CRISPR–Cas9 screening to establish that a T cell receptor (TCR) recognized and killed most human cancer types via the monomorphic MHC class I-related protein, MR1, while remaining inert to noncancerous cells. Unlike mucosal-associated invariant T cells, recognition of target cells by the TCR was independent of bacterial loading. Furthermore, concentration-dependent addition of vitamin B-related metabolite ligands of MR1 reduced TCR recognition of cancer cells, suggesting that recognition occurred via sensing of the cancer metabolome. An MR1-restricted T cell clone mediated in vivo regression of leukemia and conferred enhanced survival of NSG mice. TCR transfer to T cells of patients enabled killing of autologous and nonautologous melanoma. These findings offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Nature Publishing Group
ISSN: 1529-2908
Date of First Compliant Deposit: 28 January 2020
Date of Acceptance: 10 December 2019
Last Modified: 27 Mar 2024 16:13
URI: https://orca.cardiff.ac.uk/id/eprint/128952

Citation Data

Cited 119 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics